Related Experiment Videos
The mucin antigens: what are we measuring?
M R Price1, S Briggs, M J Scanlon
1Cancer Research Campaign Laboratories, University of Nottingham.
Disease Markers
|May 1, 1991
Summary
Breast cancer serum contains mucin-like glycoproteins that can be used as differentiation markers. The study highlights the clinical potential of these mucin antigens and specific antibody recognition in breast cancer research.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- Serum of breast cancer patients contains high molecular weight, mucin-like glycoproteins.
- These glycoproteins are considered differentiation markers for normal epithelia, especially mammary epithelium.
- Previous identification relied on antibodies against milk fat globule membranes, tumor extracts, or purified mucins.
Purpose of the Study:
- To investigate the clinical potential of mucin antigens in breast cancer studies.
- To demonstrate the specificity of immune recognition for complex polymorphic glycoproteins at the amino acid level.
Main Methods:
- Utilized the anti-urinary mucin antibody, C595.
- Examined immune recognition of mucin antigens in breast cancer patient serum.
- Analyzed specificity at the individual amino acid level within the mucin protein core.
Main Results:
- The anti-urinary mucin antibody C595 showed potential in breast cancer studies.
- Demonstrated exquisite specificity of immune recognition for a complex polymorphic glycoprotein.
- Identified immune recognition occurring at the level of individual amino acids within the APDTRPAP domain.
Conclusions:
- Mucin antigens in breast cancer serum hold clinical potential for diagnosis and monitoring.
- The antibody C595 exhibits high specificity, recognizing individual amino acids in the mucin core.
- This research underscores the importance of specific antibody-target interactions in understanding complex glycoproteins in cancer.